Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q3 FY22 results · Oct–Dec 2021
Alivus Life Sciences reported revenue from operations of ₹522.50 crore and net profit of ₹103.71 crore for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 522.50 | — | — | 561.76 | −7.0% |
| Other income | 3.53 | — | — | 2.09 | +69.2% |
| Total income | 526.03 | — | — | 563.85 | −6.7% |
| Profit before tax | 139.80 | — | — | 152.53 | −8.4% |
| Net profit for the period | 103.71 | — | — | 115.20 | −10.0% |
| EPS, basic (₹) | 8.65 | — | — | 9.83 | −12.0% |
| Net margin (%) | 19.8 | — | 20.5 |
Standalone
- Filed with BSE
- 08 Feb 2022, 20:14 IST
- Board meeting
- 08 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE